Lung cancer screening: promise and pitfalls

Area of Science:

• Pulmonary Medicine
• Radiology
• Oncology

Background:

• The National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose helical computed tomography (LDCT) for lung cancer screening.
• LDCT screening showed a 20% reduction in lung cancer mortality and a 6.7% reduction in all-cause mortality compared to chest X-ray.

Purpose of the Study:

• To summarize the findings of the NLST regarding LDCT screening for lung cancer.
• To discuss the potential benefits and harms of LDCT screening.
• To identify opportunities for optimizing the implementation of lung cancer screening programs.

Main Methods:

• The study is based on the results of the National Lung Screening Trial (NLST), a randomized trial comparing LDCT to chest X-ray.
• Analysis of data from NLST and other published studies informed the development of lung cancer screening guidelines.

Main Results:

• LDCT screening resulted in a 20% decrease in lung cancer mortality and a 6.7% decrease in all-cause mortality.
• Key harms associated with LDCT screening include radiation exposure, high false-positive rates, and overdiagnosis.

Conclusions:

• LDCT screening holds significant potential for reducing lung cancer mortality.
• Optimizing screening implementation requires standardized practices, refined risk assessment, integrated smoking cessation programs, and broad stakeholder education.
• Incorporating validated biomarkers can further enhance screening program effectiveness.